Current Report Filing (8-k)
September 13 2019 - 1:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________
FORM 8-K
___________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2019
Commission File Number: 000-26181
AngioGenex, Inc.
(Exact name of small business issuer as specified in its charter)
|
| |
Nevada
|
|
86-0945116
|
(State or other jurisdiction of incorporation or organization)
|
|
(IRS Employer Identification No.)
|
|
425 Madison Ave., Suite 902, New York, New York 10017
|
(Address of principal executive offices)
|
|
(212) 644-2100
|
(Issuer's telephone number, including area code)
|
|
|
(Former name, former address and former fiscal year,
If changed since last report)
|
| |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Items to be Included in this Report
SECTION 5. CORPORATE GOVERNANCE AND MANAGEMENT
ITEM 5.02 Departure of Principal Officer; Appointment of Principal Officer
(a) Departures of Principal Officer
Effective September 12, 2019, Dr. Robert Benezra, the President and Chief Executive Officer and a Director, tendered his resignation. There were no disagreements between Dr. Benezra and our Board of Directors regarding any business practices or procedures. Dr, Benezra will continue to serve as the Chairman of the Companys Scientific Advisory Board.
(d) Appointment of Principal Officers
On September 12, 2019, Mr. Michael Aronstein, the Chairman of the Companys Board of Directors, was appointed as the Companys President and Chief Executive Officer:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AngioGenex, Inc. (Registrant)
Date: September 13, 2019
By: /s/ Michael Strage
Michael Strage
Chief Admin Officer
|
AngioGenex (CE) (USOTC:AGGX)
Historical Stock Chart
From Apr 2024 to May 2024
AngioGenex (CE) (USOTC:AGGX)
Historical Stock Chart
From May 2023 to May 2024